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doi:10.1016/j.ejvs.2009.06.009Abstract Diabetes mellitus (DM) is an independent predictor for morbidity and mortality in
the general population, which is even more apparent in patients with concomitant cardiovas-
cular risk factors. As the prevalence of DM is increasing, with an ageing general population, it is
expected that the number of diabetic patients requiring surgical interventions will increase.
Perioperative hyperglycaemia, without known DM, has been identified as a predictor for
morbidity and mortality in patients undergoing surgery. Moreover, early studies showed that
intensive blood-glucose-lowering therapy reduced both morbidity and mortality among
patients admitted to the postoperative intensive care unit (ICU). However, later studies have
doubted the benefit of intensive glucose control in medicalesurgical ICU patients. This article
aims to comprehensively review the evidence on the use of perioperative intensive glucose
control, and to provide recommendations for current clinical practice. A systematic review
was performed of the literature on perioperative intensive glucose control. Based on this liter-
ature review, we observed that intensive glucose control in the perioperative period has no
clear benefit on short-term mortality. Intensive glucose control may even have a net harmful
effect in selected patients. In addition, concerns on the external validity of some studies are
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628 J.P. van Kuijk et al.perioperative setting. We propose that guidelines recommending intensive glucose control
should be re-evaluated. In addition, moderate tight glucose control should currently be re-
garded as the safest and most efficient approach to patients undergoing major vascular
surgery.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Figure 1 Schematic representation for the balance of peri-
operative blood glucose status.Diabetes mellitus (DM) currently affects over 40 million
people in the European Union alone. Importantly, the
prevalence of DM is strongly related to age; over 20% of the
population aged above 60 years is diabetic.1 With an ageing
Western population, the impact of diabetes is a major
health burden and will increase dramatically within the
next 20 years.2
Simultaneously, ageing of the population will also cause
an increase of patients with peripheral arterial disease
(PAD). The combination of an increasing incidence of dia-
betes and PAD will result in an increasing number of pre-
diabetic patients requiring vascular surgical procedures.
Patients with diabetes or an impaired glucose tolerance
(IGT) are more prone to dysregulation of glucose haemo-
stasis, especially during surgical stress or critical illness.
This condition develops independently of previous diag-
nosed diabetes and is also called stress diabetes or diabetes
of injury.3,4 These hyperglycaemic conditions have been
identified as an important risk factor (Relative Risk 3.9) for
morbidity and mortality in patients undergoing surgery.5
Since glucose dysregulation has such an impact on
postoperative and long-term outcome in these patients,
adequate preoperative screening as well as perioperative
and postoperative glucose management are of critical
importance. Therefore, the aim of the current systematic
review is to (1) provide an overview of recent evidence on
preoperative screening of vascular surgery patients with
respect to diabetes and glucose tolerance, and (2) to
provide an overview of recent evidence on monitoring and
treatment strategies for adequate glucose regulation in the
perioperative period during vascular surgical procedures.
Pathophysiology of glucose regulation
disorders
In patients with pre-diabetes, many factors are involved in
determining the glycaemic response, both during a stable
homeostatic phase and during stressfulmoments such as
surgery or critical illness. During normal daily activities,
there is a relative balance between glucose metabolism and
insulin secretion, resulting in slightly elevated blood
glucose levels. These elevated glucose levels do not result
in classical diabetic symptoms. However, the abundance of
glucose molecules in the blood results in microvascular
damage of the kidneys, retina and peripheral nerves.6
The glucose balance can be easily disturbed by stress
and fasting associated with surgery. During the time
between the preoperative period and the postoperative
recovery the following factors may change radically: (1)
insulin secretory capability, (2) insulin sensitivity, (3)
overall metabolism, and (4) nutritional intake.7 There is an
imbalance in blood-glucose-lowering and stimulating
agents, leading to hyperglycaemia and excess circulatingfree fatty acids.7 These free fatty acids require aerobic
metabolism, and result in increased oxygen consumption
with major consequences, especially in the presence of
concomitant myocardial ischaemia. Free fatty acids also
inhibit myocardial glucose use, decrease contractility,
predispose to develop arrhythmias and increase accumu-
lation of free radicals.8 In addition to this, hyperglycaemia
causes fluid shifts (glycosuria and dehydration), promotes
the inflammatory response leading to endothelial dysfunc-
tion, enhances platelet aggregation and reduces immune
function by impaired complement activity.4 In summary,
hypoglycaemia results from predominance of the glycaemic
effects of a decrease in carbohydrate intake and an
increase in circulating insulin. Hyperglycaemia is charac-
terised by a predominance of the glycaemic effects of an
increase in stress hormones and a decrease of circulating
insulin levels (Fig. 1 ).
Preoperative testing for diabetes
In pre-diabetic patients, elevated glucose levels are usually
present for 7e10 years before the diagnosis of DM is made.9
Screening for glucose regulation disorders can be per-
formed by either fasting plasma glucose (FPG) measure-
ment or oral glucose tolerance testing (OGTT). Fasting
plasma glucose measurement includes a blood glucose
measurement in the morning after overnight fasting. Oral
glucose tolerance testing included a fasting glucose
measurement and an additional blood glucose sample 2 h
after the ingestion of 75 g oral glucose load. Impaired
fasting glucose is defined as plasma glucose of 100e
125 mg dl1 (5.6e6.9 mmol l1) and IGT as plasma glucose
of 140e199 mg dl1 (7.8e11.1 mmol l1). According to the
American Diabetes Association guidelines, DM was defined
as FPG 126 mg dl1 (7.0 mmol l1)and/or plasma
glucose 200 mg dl1 (11.1 mmol l1).2 Several prospective
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additional value of OGTT to FPG, with respect to the
relationship between hyperglycaemia and risk of cardio-
vascular disease. The Diabetes Epidemiology: Collaborative
Analysis of Diagnostic Criteria in Europe (DECODE) Study
group showed that the addition of OGTT to FPG significantly
improved the prediction of all-cause mortality (hazard ratio
1.73; 95% confidence interval (CI) 1.5e2.1), cardiovascular
disease (hazard ratio 1.42; 95% CI 1.02e1.9) and coronary
heart disease (hazard ratio 1.56; 95% CI 1.03e2.4).9 These
results were confirmed by The Cardiovascular Health Study
that also showed an association between FPG lev-
els> 6.3 mmol l1 and increased cardiovascular risk (hazard
ratio 1.66; 95% CI 1.4e2.0).10 Furthermore, this population-
based study showed the additional value of the OGTT to
FPG measurement, as 2-h glucose loading level was asso-
ciated with a linearly increased cardiovascular risk (hazard
ratio 1.02; 95% CI: 1.00e1.04) per 0.6 mmol l1 increase in
blood glucose level 2 h after glucose loading.
In a recent study, van Kuijk et al. studied the additional
effect of OGTT to FPG for the detection of IGT and DM in
patients scheduled for major vascular surgery as well.11 A
strong additional effect on diagnosing IGT and DM by OGTT
was shown. Seventy-five percent of the patients with IGT
and 72% of the patients with DM would have been missed, if
only the fasting glucose levels were measured (Fig. 2 ).
Importantly, as DM is one of the cardiovascular risk factors
of the adapted Lee Risk index, detection of new DM in
patients scheduled for major vascular surgery results in an
increased risk score.12 In patients with other concomitant
cardiovascular risk factors, addition of DM will result in
a need for more extended preoperative testing and subse-
quent treatment. However, preoperative testing for
glucose regulation disorders is not routinely performed in
vascular surgery patients.
Currently, the use of preoperative FPG or OGTT is only
recommended by the European Society of Cardiology/
European Association for the Study of Diabetes in patients
undergoing surgery with two or more clinical Heart Asso-
ciation (ACC/AHA) guidelines cardiovascular risk factors.13
The American College of Cardiology/American for preop-
erative management in patients with PAD undergoing non-
cardiac surgery, recommend an FPG measurement, but not
a preoperative glucose-loading test.6Figure 2 Additional value of Oral Glucose Tolerance Testing
over Fasting Plasma Glucose measurement. Figure reproduced
from reference,19 with permission from the publisher.Outcome after vascular surgery in pre-diabetic
patientsIn vascular surgery patients, preoperative elevated gly-
cated haemoglobin and preoperative impaired fasting
glucose have been related to an increase in cardiovascular
events and/or all-cause mortality during follow-up.14,15
O’Sullivan et al. showed that patients scheduled for
vascular surgery without DM but with suboptimal glycated
haemoglobin levels (6e7%) had a significantly higher inci-
dence of overall 30-day mortality compared with patients
having glycated haemoglobin levels <6% (56.5% vs. 15.7%
p< 0.001).14 This was confirmed by Feringa et al. in
vascular surgery patients with IGT and/or DM detected by
OGTT, which had a 2.2efold increased risk for ischaemia,
3.8-fold for troponin T release, 4.3-fold for 30-day cardiac
events, and 2.7-fold for long-term cardiovascular events.15
The presence of DM is an established and risk factor for
atherosclerotic coronary disease and PAD, independent of
other atherogenic risk factors, with a relative risk averaging
twofold for men and threefold for women.16 Patients with
DM can have two types of vascular disease: (1) a non-
occlusive microcirculatory dysfunction involving the
kidneys, retina and peripheral nerves and (2) a macro-
angiopathy characterised by atherosclerotic lesions of the
coronary and peripheral arterial circulation.17 Based on
these pathogenic mechanisms, it could be assumed that
patients scheduled for vascular surgery and concomitant
DM would have an increased risk of morbidity and mortality
due to atherosclerotic disease. However, several studies
have shown conflicting results regarding the association
between DM and the risk of cardiovascular morbidity and
mortality in vascular surgery patients. Malmstedt et al.
studied a group of diabetic patients who underwent
infrainguinal bypass surgery.18 They observed an increased
risk of renal insufficiency and infected foot ulcer in patients
with perioperative hyperglycaemia. This was confirmed by
Ramos et al. who demonstrated an increased risk of post-
operative infections after vascular surgery in patients with
perioperative hyperglycaemia.19 Importantly, this was
independent of the diabetic status. Van Kuijk et al.
recently showed that patients with IGT or DM detected by
OGTT have an increased risk for the development of
cardiovascular events during follow-up11 (Fig. 3 ). However,
other studies demonstrated that patients with DM do not
appear to be at increased risk of death after intermediate20
or high-risk surgery.21 Some of these studies suffered from
a small number of adverse outcomes and incomplete
documentation of important co-morbidities. In response to
this controversy, Axelrod et al. performed a large study in
patients undergoing elective major vascular surgery. They
demonstrated that in univariable analysis, patients with DM
had a higher incidence rate of perioperative death (3.9% vs.
2.6%, pZ 0.001) and cardiovascular complications (3.3% vs.
2.6%, pZ 0.01) compared to patients without diabetes.
After controlling for co-morbid conditions, procedure type
and diabetic complications, only insulin-dependent dia-
betes was an independent risk factor for death or cardio-
vascular complications.22 However, this study mainly
included lower-risk patients with known DM, while the risk
of diabetes is most clear in intermediate- and high-risk
Figure 3 Cardiovascular event free survival during long-term
follow-up after glucose-loading test in patients undergoing
major vascular surgery. Figure reproduced from reference,19
with permission from the publisher.
630 J.P. van Kuijk et al.patients. Recently, Protack et al. investigated the influence
of DM as part of the metabolic syndrome in patients who
underwent carotid revascularisation.23 Vascular surgery
patients with metabolic syndrome and/or DM had an
increased risk of perioperative morbidity as well as stroke,
myocardial infarction and major adverse events during
long-term follow-up, compared with those without meta-
bolic syndrome. Overall, vascular surgical patients with
concomitant diabetes are more likely to experience peri-
operative and long-term cardiac events.
Perioperative monitoring and treatment of
blood glucose level disorders
Aims of perioperative management
In 2001, Van den Berghe et al. published the first Leuven
study, a randomised controlled trial of critically ill patients,
which showed that tight glucose control significantly
reduced hospital morbidity and mortality.24 Other studies
have shown that tight glycaemic control is associated with
decreased infection rates and improved survival during
cardiac surgery,25 in the setting of acute neurologic injury26
and acute myocardial infarction.27 Based on these studies,
several professional societies, including the American Dia-
betes Association and the American Association of Clinical
Endocrinologists, now recommend tight glucose control in
all surgical or medical critically ill adults.2,24,28 Based on
the pathophysiologic mechanisms of symptomatic DM and
the study by Van den Berghe, prevention of hyperglycaemic
periods has been suggested to not only decrease the risk of
dehydration, electrolyte abnormalities and diabetic
ketoacidosis but also improved wound healing.24 Therefore,
the following treatment aims are provided for known dia-
betic patients: (1) avoid hypoglycaemia, (2) avoid excessive
hyperglycaemia (main aim< 11 mmol l1), (3) avoid loss of
electrolytes (potassium, magnesium and phosphate), and
(4) prevent lipolysis and proteolysis.29,30
However, patients with unknown DM or IGT are not
sufficiently controlled during the perioperative period. Thisstatus of relative insulin deficiency is associated with an
increased secretion of catabolic hormones not only during
surgery, but also in critical illness and trauma. As patients
undergoing surgery are routinely not extensively tested for
IGT or unknown DM, hyperglycaemic episodes may have
their first occurrence during surgery or critical illness.31
Especially, older patients without known DM are prone to
the development of critical illness-induced or surgery-
induced hyperglycaemia (blood glucose of 11 mmol1).
Treatment aims in these patients are mainly directed at
avoidance of hyperglycaemia and loss of electrolytes.
Hyperglycaemic periods are most often treated with short-
acting insulin therapy. However, the risk of hypoglycaemia
may not be underestimated and can have serious adverse
effect, including seizure, coma or even death.
Influence of perioperative hyperglycaemia and
treatment on outcome
Postoperative outcome in patients with and without known
DM has extensively been studied in intensive care unit (ICU)
patients. However, data regarding the influence of glucose
regulation disorders on the outcome after major vascular
surgery are relatively scarce. Therefore, treatment
recommendations for vascular surgery patients are based
on the current knowledge in ICU patients. For the current
systematic review, all studies in surgical and combined
surgicalemedical ICU patients were selected and reviewed
to provide an overview of mortality rates and other
outcome parameters (Table 1 ).
Intensive Care Unit patients
Known DM is present in up to 26% of the critically ill patients
requiring intensive-care treatment.24,43 If a critically ill
patient requires more than 5 days intensive-care treat-
ment, there is a 20% risk of death and substantial
morbidity.44 Intensive-care patients with DM are known to
have higher risk of severe infections and failure of vital
organs, thereby amplifying the risk of an adverse outcome.
However, not only patients with known DM have a higher
risk of adverse outcome after ICU treatment but also those
with new-onset DM, presenting with perioperative hyper-
glycaemia is common in critically ill patients, without
known DM. The occurrence of hyperglycaemia in non-dia-
betics has been seen to be associated with an increased
morbidity and mortality in those patients.45
Randomised controlled trials
Van den Berghe et al. performed the first single-centre
randomised (but unblinded) controlled trial (RCT) to study
the influence of intensive insulin therapy compared to
conventional treatment in 1548 surgical ICU patients.24
They hypothesised that hyperglycaemia or relative insulin
deficiency during critical illness may compare to morbidity
and mortality. Target blood glucose levels were 9.9e
11.0 mmol l1 and 4.4e6.1 mmol l1 in the conventional
and intensive group, respectively. The study showed a 34%
relative risk reduction in overall in-hospital mortality in the
intensive treatment group. However, this reduction was
observed only in patients requiring more than 5 days of
Table 1 Characteristics of the selected studies for the systematic review on perioperative intensive blood-glucose-lowering in
surgical and medicalesurgical patients.
Author Patients
(N )
DM
(%)
Mean age
(years)
Type of
surgery
Glucose target
(mmol/l)
Mortality RR
(95%CI)
Surgical ICU patients
He31 188 18 65.5 Abdominal/Neuro 4.4e6.1 Not reported
Stecher32 117 13 52.6 Abdominal/trauma 4.4e6.1 1.05 (0.45e2.46)
Grey33 61 12 55.6 General 4.4e6.6 0.53 (0.17 - 1.69)
Kia34 265 26 68.2 Abdominal 4.1e6.3 1.74 (0.86e3.51)
All surgical 635 20 62.9 4.1e6.6 1.12 (0.60e2.10)
SurgicaleMedical ICU patients
Mitchell35 70 14 65.5 Surgical 62% 4.4e6.1 3.00 (0.89e10.16)
Wang36 116 11 66.2 Surgical 15% 4.4e6.1 0.27 (0.13e0.57)
Brunkhorst37 537 30 64.6 Surgical 53% 4.4e6.1 0.95 (0.71e1.27)
Iapichino38 72 17 62.3 Surgical 32% 4.4e6.1 Not reported
Mackenzie39 240 83 64.5 Surgical 46% 4.0e5.9 0.82 (0.58e1.15)
Arabi40 523 40 52.4 Surgical 17% 4.4e6.1 0.84 (0.64e1.09)
Devos41 1101 19 64.8 Surgical 58% 4.4e6.1 1.20 (0.93e1.55)
Azevedoe 337 31 56.2 Surgical 40% 4.4e6.6 0.91 (0.62e1.34)
NICE-SUGAR42 6104 20 60.4 Surgical 34% 4.5e6.0 1.14 (1.02e1.28)
Overall 3631 23 61.8 4.0e6.6 0.96 (0.80e1.15)
e Denotes unpublished data.
Perioperative Glucose Monitoring in Vascular Surgery 631intensive-care treatment. Regression analysis of these
results indicated that the lowered blood glucose rather
than the insulin dose was related to the reduction in
mortality and morbidity.46 Since the first study by Van den
Berghe et al., additional studies have been performed to
determine if the benefits and risks of tight glucose control
are generalisable to surgical ICU patients, medical ICU
patients and operating rooms.43,47 Several studies have
shown inconsistent results as some showed a positive result
on mortality and other neutral or even negative results.
In 2006, Van den Berghe et al. performed a second RCT
to compare intensive insulin treatment and conventional
therapy in 1200 medical ICU patients.48 Intensive insulin
treatment decreased ICU and hospital length of stay,
ventilator days and incidence of kidney injury. However, it
did not reduce overall mortality in the total study pop-
ulation. Again, in patients with longer ICU stay (3 days)
intensive insulin treatment was associated with a decrease
in mortality from 53% to 43%. In contrast, there was a trend
towards higher mortality rates in the subgroup of patients
with ICU stays shorter than 3 days. Additionally, the
increased occurrence of hypoglycaemia in the intensive
treatment group (19% vs. 3%) was an independent predictor
of death in multivariable analysis. Recently, the European
GLUCONTROL trial (mixed medicalesurgical ICU patients)
and the VISEP trial (medical ICU patients) were stopped
early due to safety concerns given a high incidence of
severe hypoglycaemia and serious adverse events.37,49
The recent Normoglycaemia in Intensive Care Evaluation
e Survival Using Glucose Algorithm Regulation (NICE-
SUGAR) trial was designed to test the hypothesis that
intensive glucose control reduces mortality at 90 days in
medicalesurgical ICU patients. Recent published results
showed that patients with intensive insulin treatment had
an increased risk for overall mortality within the first 90days from ICU stay (odds ratio (OR) 1.14; 95% CI 1.02e1.28,
pZ 0.02).42 In addition, severe hypoglycaemia was signifi-
cantly more often noted in patients with tight glucose
control (6.8% vs. 0.5%). Subgroup analysis of surgical vs.
non-surgical ICU patients showed no significant difference
for the treatment effect. These results suggest that
achieving normoglycaemia in medicalesurgical ICU patients
does not necessarily benefit ICU patients, but may be even
harmful.
Meta-analysis
Wiener et al. recently summarised all intensive insulin
treatment studies in a meta-analysis.50 They included 29
randomised controlled trials regarding tight glucose
control in critically ill adults, totalling 8432 patients. The
included studies were subdivided according to the ICU
setting (surgical, medical or combined) and to glucose
goal (tight vs. moderate glucose control). No significant
differences in-hospital mortality rates were detected,
even not when mortality rates were subdivided for type of
ICU setting and/or glucose target. Tight glucose control
significantly reduced the risk of septicaemia in surgical
ICU patients, when compared with usual glucose control.
However, this was at the cost of an over fivefold increased
in the risk of hypoglycaemia when the tight glucose
control regimen was used (relative risk 5.13;, 95% CI
4.09e6.43). The meta-analysis had the usual limitations of
pooled data and the fact that some of the included
studies were relatively small. In addition to this, the
analyses on hospital mortality were underpowered to
detect the 1.7% difference in mortality rate that was
identified.
As the study by Van den Berghe is regarded as the main
basis for the present guidelines on tight glucose control in
critically ill patients, it is remarkable that this study was
632 J.P. van Kuijk et al.identified as having outlying results by tests of heteroge-
neity in the meta-analysis by Wiener. Three important
reasons for these different results are: (1) bias by an
unblinded trial design, (2) the unusual high mortality in the
conventional group may be the result of chance and (3)
several atypical clinical practices were performed (use of
early glucose infusion and high levels of parenteral nutri-
tion, both possibly inducing hyperglycaemia). This meta-
analysis is a large effectiveness study. In general, there is
lack of agreement for standard glycaemic control levels and
incomplete reporting in most included trials. However, as
this meta-analysis presents the effect of targeting tight
glycaemic control in several ICU settings with different
treatment regimens, the results are more generalisable.
Conclusion Intensive Care Unit patients
Although several RCTs, systematic reviews and a meta-
analysis have led to differing conclusions, many profes-
sional organizations recommend tight glucose control for
patients treated at the ICU. However, barriers to wide-
spread adoption of tight glucose control include the risk of
hypoglycaemia, concerns about the external validity of
some studies and the difficulty of achieving normoglycae-
mia in ICU patients.
Monitoring and treatment recommendations in
major vascular surgery
Patients undergoing major vascular surgery most often die
from cardiovascular co-morbidities.51 With the growing age
of the population, patients scheduled for vascular surgery
more often have additional cardiovascular risk factors at
time of surgery. Screening for glucose regulation disorders
should be performed in all patients with two or more clin-
ical risk factors. The current guidelines for patients
undergoing surgery recommend strict glucose regulation
during the perioperative phase and intensive-care treat-
ment.2,28,52 These recommendations are based largely on
one clinical trial that showed decreased mortality in
a surgical intensive care unit.24 Several large RCTs have
been provided since then; however, all of them failed to
show the same mortality benefit. We performed a critical
review of the available ICU studies and concluded that
overall mortality in patients randomised to tight glucose
regulation is not decreased compared to moderate tight
glucose control. The recent NICE-SUGAR trial also observed
an increased mortality risk for all types of ICU patients at 90
days from ICU stay, independent of diabetic status.
No randomised controlled trials specifically addressing
the monitoring and treatment of hyperglycaemia during
major vascular surgery have been performed. Therefore,
results of studies in comparable patient groups have to be
translated for this patient population. The current guide-
lines for perioperative care in PAD patients recommend
a target glucose level of <11 mmol l1 during the peri-
operative phase. Based on the current available studies,
moderate tight glucose control with a target blood glucose
level between 6.0 and 8.3 mmol l1 could be more benefi-
cial. In addition,, there is an increased risk for hypo-
glycaemia in patients with tight glucose control. Therefore,
moderate tight glucose control could have the advantage ofdecreasing the risk of both hyperglycaemia and the
prevention of hypoglycaemia during major vascular surgery.
Conclusion
A few studies regarding the influence of perioperative
blood sugar monitoring and treatment in patients under-
going vascular surgery have been performed. Based on
these studies and a diversity of studies in the intensive care
setting, patients scheduled for vascular surgery with known
DM should be treated with insulin infusion during the peri-
operative phase with a moderate tight glucose control
regimen. Unknown diabetics should be tested preopera-
tively for glucose regulation disorders if two or more clin-
ical risk factors are present. Further prospective
randomised studies need to be undertaken to establish the
absolute benefits of moderate vs. tight glucose control in
vascular surgical patients in the perioperative period.
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